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Abstract
Objective: Pulmonary disease is a leading cause of morbidity and mortality 
in rheumatoid arthritis (RA). In this study, we investigated the prevalence 
and progression of interstitial lung abnormalities (ILA) in a prospective cohort
study of 18 subjects with early RA.
Methods: Eighteen adults diagnosed with anti-citrullinated protein-antibody-
positive RA within the prior year underwent baseline high-resolution 
computed tomography (HRCT), symptom assessment, and pulmonary 
function and laboratory testing. The follow-up HRCT and clinical assessment 
were completed after 1 year.
Results: Seven of the 18 patients (39%) had baseline HRCT abnormalities 
including septal thickening, honeycombing, ground glass opacities, and/or 
traction bronchiectasis. At follow-up, 6 out of the 7 subjects (86%) with ILAs 
at baseline exhibited progression, while 10 out of 11 (91%) without ILAs at 
baseline remained stable. A higher Clinical Chronic Obstructive Pulmonary 
Disease Questionnaire score was associated with both the presence and 
progression of HRCT abnormalities (10 vs 2, p=0.045; 10 vs 2, p=0.009, 
respectively). C-reactive protein (CRP) trended higher in patients with 
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radiologic abnormalities (3.5 mg/L vs 1.1 mg/L, p=0.08) and was significantly
higher in those with progression (3.5 mg/L vs 1 mg/L, p=0.024). Smoking, 
pulmonary function, and autoantibodies were not associated with HRCT 
abnormalities.
Conclusion: ILAs are prevalent in patients with early RA. If identified at 
baseline, radiographic progression of ILAs after 1 year is likely, while those 
without ILAs at baseline are unlikely to develop new ILAs. In addition, early 
respiratory symptoms and higher CRP levels may correlate with the presence
and progression of underlying ILAs.
Keywords: Rheumatoid arthritis, interstitial lung disease, autoantibodies, 
computed tomography, disease progression
Main Points
 Radiographic interstitial lung abnormalities (ILAs) were observed in 39% 
of rheumatoid arthritis subjects without respiratory symptoms.
 At 1 year follow up, majority of patients with baseline ILAs exhibited 
radiographic progression.
 Both the presence of baseline ILAs and their progression trended with 
higher c-reactive protein levels.
 These observed ILAs raises concern for the development of interstitial 
lung disease in the future, but further studies are needed to determine 
their clinical significance.
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Introduction
The characteristic manifestation of rheumatoid arthritis (RA) is joint disease, 
although extra-articular involvement is commonly seen (1). Lung 
involvement has been reported in up to 67% of patients with RA, and it can 
involve the pleura, airways, parenchyma, and vasculature (2). In particular, 
parenchymal disease in the form of interstitial lung disease (ILD) portends a 
poor prognosis and alone can account for 10%-20% of RA-related mortality 
(3). Currently, there are no formal guidelines for clinical screening of ILD in 
RA patients, but identifying RA patients who will develop ILD can improve 
clinical prognosis.
On high-resolution computerized tomography (HRCT), RA-associated ILD can 
present as multiple radiographic patterns, including usual interstitial 
pneumonia (UIP) characterized by fibrosis and honeycombing, as well as non-
specific interstitial pneumonia (NSIP) distinguished by extensive ground glass
opacities (4-5). Imaging features of reticular thickening, honeycombing, 
traction bronchiectasis, and/or ground glass opacities, without a diagnosis of 
UIP or NSIP, have been termed interstitial lung abnormalities (ILA), and they 
are thought to represent subclinical disease (6).
Multiple cross-sectional studies using HRCT have identified a high prevalence
of ILAs in patients with early RA (7-14). However, the time course and 
significance of subtle findings of ILAs, often in the absence of significant 
respiratory symptoms, are not known. In addition, there is limited knowledge
about the factors that may be associated with the prevalence and 
progression of ILAs in RA.
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Utilizing a unique cohort of patients with both recent diagnosis of RA and 
anti-citrullinated protein/peptide antibody (ACPA) positivity, this study 
evaluated the prevalence and progression of ILAs by employing a novel 
scoring system for HRCT findings, as well as factors associated with these 
findings.
Methods
Study subjects and overall design
Eighteen consecutive individuals meeting study criteria were recruited from 
the rheumatology clinic at our institution. Study eligibility criteria included 
age >18 years, RA diagnosed within the past year (irrespective of symptom 
duration or prior treatments) by a rheumatology specialist and serum ACPA 
positivity as measured by the anti-cyclic citrullinated peptide (CCP) assay. 
Patients with existing respiratory diagnoses or additional connective tissue 
diseases were excluded.
From September 2011 to February 2013, a total of 18 patients with RA were 
enrolled. All 18 patients returned for a second visit at a median follow-up of 
14 months, range 12 to 32 months.
Respiratory symptom assessment
At the initial study visit, all subjects completed a Clinical Chronic Obstructive 
Pulmonary Disease Questionnaire (CCQ) as a standardized measure for 
assessing respiratory symptoms (15). In addition, all subjects underwent 
HRCT, pulmonary function testing (PFT), as well as laboratory testing as 
described below. After at least a year from the initial visit, all subjects 
returned for a second HRCT.
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High-resolution computerized tomography
HRCT of the chest without intravenous contrast was performed in the supine 
and prone positions using 1 mm collimation at 40 mm intervals for the high-
resolution component and 5 mm collimation at 5 mm intervals for routine 
computerized tomography (GE 750HD CT, General Electric Medical Systems, 
Chicago, USA). A single radiologist (PJ), blinded to the patient identity and 
characteristics, but not to the sequence of the scans, read, and scored the 
images as described below.
HRCT scoring system
A radiologic quantitative scoring system was created based on the 
modification of a previously published scoring system for ILD (16). Each 
HRCT was divided into three zones axially, Zone 1 being defined as above 
the under-surface of the aortic arch, Zone 3 defined as below the inferior 
right pulmonary vein, and Zone 2 between the two landmarks. Given that we
suspected the abnormalities would be subtle in majority of cases, the images
were further divided as follows for further quantification. Two representative 
slices were selected from each zone for scoring per the radiologist’s 
discretion. In addition, each slice is divided into left and right lung for a total 
of 12 sections and assessed for the presence of ILAs defined by the presence
of one or more of the following: (1) septal thickening, (2) honeycombing, (3) 
ground glass opacity (GGO), and (4) traction bronchiectasis. Each lung zone 
was scored based on a semi-quantitative estimate with a 4-point scale (0=no
involvement, 1=1%-25% involvement, 2=26%-50% involvement, 3=51%-
75% involvement, or 4=76%-100% involvement). The maximum possible 
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score for each subject is 192, shown in Table 1. Subjects were considered to 
have positive radiographic findings if any abnormalities were seen (score of 
1 or above).
Pulmonary function testing
Measured pulmonary function values included the forced expiratory volume 
in 1 second (FEV1), forced vital capacity (FVC), FEV1-to-FVC ratio, total lung 
capacity, and diffusion capacity of carbon monoxide (DLCO). Values were 
expressed as the percentage of predicated values and interpreted according 
to the American Thoracic Society recommendations (17).
Serologic testing
At the baseline study visit, blood samples were collected from each subject 
and tested for the following biomarkers: (1) antibodies to CCP (CCP3.1 
IgG/IgA ELISA; Inova Diagnostics, San Diego, USA); (2) high-sensitivity c-
reactive protein (hsCRP) using nephelometry (Dade-Behring BNII; Dade-
Behring, Deerfield, USA); and (3) rheumatoid factor (RF) by nephelometry 
(Dade-Behring BNII; Dade-Behring, Deerfield, USA).
Sputum antibody testing
Induced sputum samples were collected from each subject at the initial visit. 
The samples were processed at the University of Colorado Division of 
Rheumatology Clinical and Research Laboratory according to a previously 
published protocol (18). All samples were tested for RF isotypes IgM and IgG 
by ELISA (Quanta Lite kits; Inova Diagnostics, San Diego, USA) and anti-
CCP3.1 (IgG/IgA ELISA; Inova Diagnostics, San Diego, USA).
Statistical analysis
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All values are expressed as median with the interquartile range (IQR) for 
non-normally distributed data. In comparing baseline characteristics between
subjects with ILAs present or absent on initial HRCT, a univariate analysis 
was performed. Variables with continuous values were statistically analyzed 
using two-sided Mann-Whitney U test. Variables with categorical values were 
analyzed using Fisher’s exact test. The relationship of variables (CCQ score, 
RF level, anti-CCP3.1 level, and hsCRP level) and either the presence or 
progression of ILAs was analyzed using a multivariate regression model. For 
sputum antibodies, which are considered to be experimental variables in this
study, a two-sided Mann-Whitney U test was performed. For all analysis, a 
two-tailed p<0.05 was considered statistically significant.
Ethical considerations
This study was approved by the Institutional Review Board (approval #4422) 
in accordance to human subject rights. All subjects provided written 
informed consent.
Results
Imaging findings on HRCT
Of the 18 total subjects, 7 (39%) had ≥1 ILA on HRCT at the initial study visit;
7 (39%) had septal thickening, 3 (17%) had honeycombing, 2 (11%) had 
ground glass opacities, and 1 (6%) had bronchiectasis. At the follow-up visit 
(median 14 months), 6 of the 7 subjects (86%) with baseline ILAs 
demonstrated progression of ILAs as defined by an increased CT score, with 
a median increase of 4 points, range from 1 to 7 points (Table 2). The 
remaining 1 subject had a decrease from 2 to 0 points on follow-up. In 
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addition, 1 of 11 (9%) subjects without lung abnormalities on their initial 
HRCT scan demonstrated progression of ILAs at follow-up with a CT score 
increase from 0 to 6 points at visit 2. The other 10 subjects without ILAs at 
baseline remained without any lung abnormalities on follow-up CT imaging. 
Representative HRCT images are shown in Figure 1.
Baseline characteristics
The characteristics of the subjects at baseline are presented in Table 3. The 
median age was 52 years, 61% were female, and 39% were smokers. The 
median duration of RA symptoms prior to the baseline visit was 1 year. 61% 
have used methotrexate, and 56% have used a biologic agent. There were 
no significant differences in baseline demographic data, prior medication 
usage, or PFT values between those subjects with ILAs at baseline and those 
subjects without them.
Factors associated with ILA presence and progression
CCQ scores, autoantibody levels, and hsCRP levels were compared between 
subjects with and without ILA at baseline, and between subjects with or 
without progression on follow-up HRCT (Table 4). The CCQ scores were 
higher in both the subjects with baseline ILA findings compared to those 
without ILAs (median 10 vs 2, p=0.07), and in subjects with radiographic 
progression compared to those without it (median 10 vs 2, p=0.04), although
this association was only statistically significant in the latter. Neither anti-
CCP3.1 nor RF positivity or levels demonstrated significant associations with 
imaging findings. The hsCRP level trended positively with both the ILA 
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presence (Median 4 vs 1, p=0.06) and progression (Median 4 vs 1, p=0.08). 
However, neither comparison met statistical significance.
Sputum antibodies
Sputum RF IgM and RF IgG levels were higher in patients with ILAs present 
on HRCT at baseline; however, these differences, as well as CCP3.1 levels, 
were not statistically significant (Table 5).
Discussion
ILD is one of the most clinically impactful extra-articular manifestations in 
RA, causing significant morbidity and mortality. However, standardized 
approaches have not been established to evaluate for lung disease, either 
ILAs or ILD, at baseline, as well progression over time in patients with RA. 
This is in part due to the lack of clear understanding of the exact factors that 
predict who will develop ILA or ILD or who will progress to require clinical 
intervention.
There has been strong evidence in several cross-sectional studies that lung 
abnormalities on HRCT can be seen early and frequently, even in 
asymptomatic patients (7-14). Gabbay et al. (7) found that 58% of 36 
patients with early RA had at least one radiologic abnormality. More recently,
Chen et al. (13) published a study involving 103 patients, one of the largest 
cohorts studied thus far. The authors found that 61% of the patients 
exhibited abnormalities on CT imaging, with GGO being the more frequent 
finding. In the general population, an analysis of CT imaging in over 11,000 
subjects found that ILAs were present at a rate of only 7%-9% (19), but the 
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presence of ILAs was associated with increased all-cause mortality, 
highlighting the potential clinical implication of these findings.
Our study provides a novel perspective into lung disease in patients with 
early RA. Prior to this investigation, to the best of our knowledge, there has 
only been one other study that assessed radiologic progression of early ILA 
over time. Guchuico et al. (9) found that 33% of their 64 patients with RA 
had subclinical ILD on CT imaging. Out of these patients, 57% demonstrated 
radiologic progression after a mean follow-up of 1.5 to 2 years. This group 
identified smoking as a risk factor for having RA-ILD, and methotrexate use 
was correlated with progression. It is of note that our patient population was 
different than that studied by Guchuico et al. (20) in that the median RA 
symptom duration was only 1 year compared to 11.3-13.7 years in their 
study. Hence, we are capturing patients who are earlier in their disease 
course. Prior evidence has shown that even when treating naïve RA patients, 
there is a higher prevalence of ILAs in patients with early RA who were ACPA 
positive. Other studies have identified lung abnormalities that even predate 
the development of arthritis in seropositive patients (21-22). Thus, despite 
the shorter disease duration, our patient population would be considered at 
high risk for extra-articular disease given that they were also pre-selected as 
ACPA positive.
In choosing a scoring system to assess the prevalence and progression of 
ILAs in our patients, we reviewed several previously published studies, 
including those on RA-related ILD and idiopathic pulmonary fibrosis (9, 16, 
23-24). Given that we suspected the radiographic findings would be very 
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subtle early in the disease course, existing scoring metrics lacked 
appropriate sensitivity to detect minimal abnormalities or very small 
changes. Therefore, in this study, we divided each CT scan into 12 zones to 
be graded on a quartile scale. Given that the NSIP pattern can also be 
observed in RA, GGOs were included as a grading parameter in addition to 
septal thickening, bronchiectasis, and honeycombing.
According to this scoring algorithm, our study identified radiographic 
abnormalities in 39% of these early ACPA positive subjects, which is in 
compliance with the prevalence seen in prior studies. In our patients, the 
maximum HRCT score was 29 out of a possible 192 points. Therefore, we 
believe that we are capturing radiographic changes at a very early stage in 
these patients. This is supported by the fact that none of our subjects has 
had any prior respiratory diagnosis nor showed any significant obstruction or 
restriction on PFT.
When assessing radiographic progression, our study considered any increase
in the HRCT score to be a positive finding. Two of the subjects had only a 1-
point increase over the study period, while the rest ranged from 4 to 7 
points. A larger study of clinical outcomes is certainly needed to determine 
the minimally clinically significant difference in our scoring system. However,
our study suggests that once these ILAs are identified, they will likely 
increase after 1 year, as seen in 86% of our subjects, and it is possible that 
radiologic abnormalities may continue to progress over time to eventually 
give rise to clinically apparent disease. On the other hand, of those subjects 
with normal CT scans, the majority (91%) did not show evidence of 
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progression at the second visit. While it is unknown whether these patients 
are going to develop pulmonary involvement in the future, it appears that 
they may be at a lower risk in the short term.
Using the CCQ symptom scores and laboratory findings, we assessed the 
association between subject characteristics and the presence or progression 
of ILAs. While only the CCQ score demonstrated significant association with 
ILA progression, both the CCQ score and hsCRP levels showed a positive 
trend toward an association with baseline ILAs and radiographic progression. 
Although we cannot draw conclusions due to the small sample size, our 
analysis also showed a trend toward higher levels of sputum RF IgM and IgG 
in individuals with ILAs, and therefore, additional studies are needed to 
understand the relationship between sputum antibodies and ILD. Overall, our
findings suggest that early and subtle respiratory symptoms, as well as 
higher levels of systemic inflammation, may be a clue toward underlying 
early parenchymal lung disease in patients with RA. Notably, respiratory 
symptoms are not often routinely assessed in rheumatology clinics and may 
thus explain the findings of subclinical lung disease in RA. If the relationship 
between these symptoms and the development or progression of lung 
disease is validated in further studies, screening for early respiratory 
symptoms in rheumatology clinics may be clinically useful.
Our study has several limitations. The subjects were recruited by 
rheumatologists who were knowledgeable of the study aims, and this may 
lead to a subtle selection bias toward patients in who respiratory disease is 
suspected. Neither the CCQ nor our novel HRCT scoring system has been 
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previously validated in this subject cohort. The HRCT images were read and 
scored by only 1 thoracic radiologist, who was not blinded to our study aim 
or to the sequence of images. Thus, he might have been more biased toward
finding a change between initial and subsequent scans and hence increase 
the possibility of finding differences. However, because this is a pilot study 
gathering hypothesis generating data, we felt that the presumed increased 
sensitivity for finding variables was justified. Lastly, our small sample size 
precludes robust analyses of the association between subject variables and 
radiographic findings, and statistical analyses may overestimate the effect in
this setting. Thus, while our findings can only be taken as suggestive or 
preliminary, they do provide new and intriguing findings regarding 
longitudinal lung changes in patients with early RA.
Despite the limitations, the implication from our findings is that clinicians 
should have a high index of suspicion for underlying pulmonary 
abnormalities in patients with early RA and ACPA positivity, especially if 
respiratory symptoms or high inflammatory markers are present. If 
radiographic abnormalities are observed, findings from our small cohort 
suggest that these abnormalities may progress over time, and further follow-
up should be considered. As discussed above, additional studies are needed 
to more clearly define appropriate screening approaches that can be 
implemented in rheumatology clinics to identify lung disease, to identify 
which patients are at the highest risk for progressive lung disease (and 
especially disease that may have important clinical outcomes), and 
ultimately, to help develop effective treatments for RA-related lung disease.
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Table 1. Protocol for scoring CT chest.
Zone 1 is above the aortic arch. Zone 2 is between the aortic arch and the inferior pulmonary veins. Zone 3 is below the inferior 
pulmonary veins.
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CT Scoring Protocol
Zone 1
Slice 1 Left Slice 1 Right
12 Total
Sections
Slice 2 Left Slice 2 Right
Zone 2
Slice 3 Left Slice 3 Right
Slice 4 Left Slice 4 Right
Zone 3
Slice 5 Left Slice 5 Right
Slice 6 Left Slice 6 Right
Abnormal Findings:
Septal Thickening
Honeycombing
Ground-Glass Opacities
Bronchiectasis
Score 0 = No 
involvement
Score 1 = 1-25%
Score 2 = 26-50%
Score 3 = 51-75%
Score 4 = 76-100%
16 Point
Maximum Per
Section
192 Total
Maximum
Points
Table 2. HRCT scores in subjects with radiographic progression from visit 1 
(gray) to visit 2 (white).
Subject SEP HON GGO BRO TOTAL
1
2 1 2 0 5
8 4 0 0 12
2
1 0 0 0 1
2 0 0 0 2
3
3 0 0 0 3
4 0 0 0 4
4
9 9 0 0 18
9 9 2 9 29
5
0 0 0 0 0
6 0 0 0 6
6
6 0 0 0 6
10 2 0 0 12
7
10 0 10 0 20
12 12 0 0 24
SEP: Septal thickening; HON: Honeycombing; GGO: ground glass opacities; BRO: bronchiectasis.
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Table 3. Baseline subject characteristics. 
All Subjects
(n=18)
ILA Absent
(n=11)
ILA Present
(n=7)        p
Female, n (%) 11 (61%) 7 (64%) 4 (47%) 1.00
Age, years 52 (47-57) 49 (38-56) 52 (47-63) 0.36
RA symptom 
duration, years 1 (0.2-3) 1 (1-2) 1 (1-2) 0.68
Ever smoker, n (%) 7 (39%) 4 (57%) 3 (43%) 1.00
Methotrexate use 
(current or prior), n 
(%)
11 (61%) 7 (64%) 4 (47%) 1.00
Biologic agent use 
(current or prior), n 
(%)
10 (56%) 7 (64%) 3 (43%) 0.63
FEV1, % predicted 105 (98-110) 105 (101-109) 95 (93-114) 0.41
FEV1/FVC ratio 77 (75-81) 79 (77-81) 75 (68-82) 0.36
TLC, %predicted 107 (96-112) 109 (103-112) 96 (92-112) 0.17
DLCO, % predicted 82 (74-90) 81 (74-92) 83 (67-87) 0.34
HRCT score 0 (0-3) 0 (0-0) 5 (2-20) n/a
All values are presented as median (interquartile range) unless otherwise noted.
 “ILA present” is defined as having total score of 1 or higher on baseline HRCT. “ILA absent” is defined as baseline HRCT total score 
of 0.
ILA: interstitial lung abnormalities; RA: rheumatoid arthritis; HRCT: high-resolution computed tomography; FEV1: forced expiratory 
volume in 1 second; FVC: forced vital capacity; TLC: total lung capacity; DLCO: diffusion capacity of lungs for carbon monoxide.
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Table 4. Comparison of subject characteristics in association with ILA 
presence or progression.
All Subjects
(n=18)
ILA Absent
(n=11)
ILA Present
(n=7) p
Non-
Progresso
r
(n=11)
Progressor
(n=7) p
CCQ score 5 (1-10) 2 (1-5) 10 (5-12) 0.07 2 (0-5) 10 (5-12) 0.04
CCP3.1 
level
162 (22-
401)
182 (34-
401)
143 (9-
401) 0.57
83 (1-
279)
201 (22-
401) 0.63
RF level 19 (10-81) 16 (10-81) 30 (10-518) 0.12
15 (10-
55)
51 (10-
518) 0.16
hsCRP level 1 (1-4) 1 (1-3) 4 (1-20) 0.06 1 (1-3) 4 (1-20) 0.08
All values are presented as median (interquartile range).
“ILA present” is defined as having total score of 1 or higher on baseline HRCT. “ILA absent” is defined as baseline HRCT total score of
0. “Progressor” is defined as having an increase in total score of 1 point or more on follow-up HRCT by 1 point or more. “Non-
progressor” is defined as stable or decreased score on follow-up HRCT. 
ILA: interstitial lung abnormalities; CCQ: Clinical COPD Questionnaire; CCP: cyclic citrullinated peptide; RF: rheumatoid factor; hsCRP: 
high-sensitivity c-reactive protein.
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Table 5. Comparison of sputum antibody levels.
All Subjects
(n=18)
ILA Absent
(n=11)
ILA Present
(n=7) P-value
Sputum CCP3.1 level 112 (53-210) 108 (36-232) 116 (74-202) 0.59
Sputum RF IgM level 7 (2-101) 6 (2-11) 61 (6-102) 0.17
Sputum RF IgG level 47 (31-81) 43 (20-79) 60 (34-87) 0.24
All values are presented as median (interquartile range).
ILA: interstitial lung abnormalities; CCP: cyclic citrullinated peptide; RF: rheumatoid factor; IgM: immunoglobulin M; IgG: 
immunoglobulin G.
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Figure 1. a-d. Representative HRCT images. Subject with baseline HRCT 
score of 20 (left) vs 13 months follow-up score of 24 (right) (a, b); subject 
with baseline HRCT score of 0 (left) vs 13 months follow-up score of 6 (right) 
(c, d).
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